Cadila says no observation by USFDA on Ahmedabad R&D facility; stock slips 2%

At the end of the inspection, no observations (483) have been issued, the company added.

Mar 22, 2019 09:03 IST India Infoline News Service

Cadila Healthcare
Shares of Cadila Healthcare slipped 2% in the last hour of the trading session on the BSE. "USFDA inspected the Pharmaceutical Technology Centre (PTC), the company's state-of-the-art R&D facility located at Ahmedabad, dedicated to new product development of various niche dosage forms including solid oral, parenteral, pulmonary, oncology, ointment & creams and transdermal, from March 18 to March 22, 2019," the company said in the BSE filing.

At the end of the inspection, no observations (483) have been issued, the company added.

Cadila Healthcare Ltd is currently trading at Rs332.90 down by Rs5.1 or 1.51% from its previous closing of Rs338 on the BSE. The scrip opened at Rs340.50 and has touched a high and low of Rs341.95 and Rs330.50 respectively.

The BSE group 'A' stock of face value Rs1 has touched a 52-week high of Rs432.40 on September 10, 2018, and a 52-week low of Rs306.35 on February 15, 2019. Last one week high and low of the scrip stood at Rs349.40 and Rs328.50 respectively.

Related Story